Dynavax to Present Data on Phase 2/3 Clinical Trial of HEPLISAV(TM) Hepatitis B Vaccine at ICAAC 2005
BERKELEY, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Dynavax TechnologiesCorporation (Nasdaq: DVAX) announced that safety and efficacy data from the company's Phase 2/3 clinical trial of HEPLISAV, its ISS-based hepatitis B vaccine, compared to GlaxoSmithKline's Engerix-B(R) vaccine in an older adult
population will be presented in a poster session at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), in Washington, DC.
The data will be presented by Dr. Seng Gee Lim, Department of Medicine, Division of Gastroenterology, National University Hospital, Singapore.
The poster is entitled, "Recombinant Hepatitis B Surface Antigen (rHBsAg) Co-administered with an Immunostimulatory Phosphorothioate Oligonucleotide (1018 ISS) Provides Superior Protection in Older Subjects."
The Phase 2/3 trial was conducted by Dr. Lim and by Dr. Chow Wan Cheng of the Singapore General Hospital. The poster session, number 87, is scheduled for Saturday,
December 17, 2005, 10:00-11:30 am Eastern Time, in Exhibit Hall B of the Washington Convention Center.
The Dynavax poster number is 221.
The poster will be available on the ICAAC website at the time of the poster session.
About Dynavax
Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary
approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune
system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA(TM), a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2/3 clinical trial and in a supportive clinical trial in
ragweed-allergic children; HEPLISAV(TM), a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.
prnewswire.com |
